LRP1B-a prognostic marker in tubo-ovarian high-grade serous carcinoma

Hum Pathol. 2023 Nov:141:158-168. doi: 10.1016/j.humpath.2023.09.001. Epub 2023 Sep 22.

Abstract

Low-density lipoprotein (LDL) receptor-related protein 1B (LRP1B) is a member of the LDL receptor family and has often been discussed as a tumor suppressor gene, as its down-regulation is correlated with a poor prognosis in multiple carcinoma entities. Due to the high metastasis rate into the fatty peritoneal cavity and current research findings showing a dysregulation of lipid metabolism in tubo-ovarian high-grade serous carcinoma (HGSC), we questioned the prognostic impact of the LRP1B protein expression. We examined a well-characterized large cohort of 571 patients with primary HGSC and analyzed the LRP1B protein expression via immunohistochemical staining (both in tumor and stroma cells separately), performed precise bioimage analysis with QuPath, and calculated the prognostic impact using SPSS. Our results demonstrate that LRP1B functions as a significant prognostic marker for overall survival (OS) and progression-free survival (PFS) in HGSC on the protein level. High cytoplasmic expression of LRP1B in tumor, stroma, and combined tumor and stroma cells has a significantly positive association with a mean prolongation of the OS by 42 months (P = .005), 29 months (P = .005), and 25 months (P = .001), respectively. Additionally, the mean PFS was 18 months longer in tumor (P = .002), 19 months in stroma (P = .004), and 19 months in both cell types combined (P = .01). Our results remained significant in multivariate analysis. We envision LRP1B as a potential prognostic tool that could help us understand the functional role of lipid metabolism in advanced HGSC, especially regarding liposomal medications.

Keywords: HGSC; HGSOC; LRP1B; Prognostic marker; Tubo-ovarian carcinoma.

MeSH terms

  • Cystadenocarcinoma, Serous* / pathology
  • Fallopian Tube Neoplasms* / pathology
  • Female
  • Humans
  • Ovarian Neoplasms* / pathology
  • Prognosis
  • Progression-Free Survival
  • Receptors, LDL / therapeutic use

Substances

  • LRP1B protein, human
  • Receptors, LDL